PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt

Standard

PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D) : Cost Implications For Denmark. / Purdy, C; Bytzer, P M; Pimentel, M.M.; Magar, R.

I: Value in Health, Bind 18, Nr. 7, 11.2015, s. A350.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt

Harvard

Purdy, C, Bytzer, PM, Pimentel, MM & Magar, R 2015, 'PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark', Value in Health, bind 18, nr. 7, s. A350. https://doi.org/10.1016/j.jval.2015.09.635

APA

Purdy, C., Bytzer, P. M., Pimentel, M. M., & Magar, R. (2015). PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark. Value in Health, 18(7), A350. https://doi.org/10.1016/j.jval.2015.09.635

Vancouver

Purdy C, Bytzer PM, Pimentel MM, Magar R. PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark. Value in Health. 2015 nov.;18(7):A350. https://doi.org/10.1016/j.jval.2015.09.635

Author

Purdy, C ; Bytzer, P M ; Pimentel, M.M. ; Magar, R. / PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D) : Cost Implications For Denmark. I: Value in Health. 2015 ; Bind 18, Nr. 7. s. A350.

Bibtex

@article{840987eb3dad4f5f8b9d52ef22d35f03,
title = "PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): Cost Implications For Denmark",
keywords = "Journal Article",
author = "C Purdy and Bytzer, {P M} and M.M. Pimentel and R Magar",
year = "2015",
month = nov,
doi = "10.1016/j.jval.2015.09.635",
language = "English",
volume = "18",
pages = "A350",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier",
number = "7",

}

RIS

TY - ABST

T1 - PMD34 A Novel Ibs Diagnostic Blood Panel Can Enhance A Positive Diagnostic Strategy Versus A Strategy Of Exclusion For Patients With Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D)

T2 - Cost Implications For Denmark

AU - Purdy, C

AU - Bytzer, P M

AU - Pimentel, M.M.

AU - Magar, R

PY - 2015/11

Y1 - 2015/11

KW - Journal Article

U2 - 10.1016/j.jval.2015.09.635

DO - 10.1016/j.jval.2015.09.635

M3 - Conference abstract in journal

C2 - 26531981

VL - 18

SP - A350

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 7

ER -

ID: 179133759